This country visit report presents the findings of a case study into outbreaks of Shiga toxin/verocytotoxin-producing Escherichia coli (STEC/VTEC) at childcare facilities in Ireland, conducted in November 2018.
To support countries in the European Union/European Economic Area (EU/EEA) in their review of preparedness system planning, ECDC launches an operational checklist for health emergency preparedness for imported cases of high consequence infectious diseases.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 19-26 October 2019 and includes updates on chikungunya, dengue, eastern equine encephalitis, Ebola virus, influenza, mass gathering monitoring in Japan.
This issue covers the period 6-12 October 2019 and includes updates on Ebola virus disease, extensively drug-resistant Klebsiella pneumoniae, West Nile virus, mass gathering monitoring (Japan, Rugby World Cup 2019), Poliomyelitis, Measles, Zika virus disease, seasonal influenza, XDR-Typhoid fever.
In 2017, 8.3% (11 787) of the patients who stayed in intensive-care units (ICUs) for more than two days presented with at least one ICU-acquired healthcare-associated infection (HAI) under surveillance (pneumonia, bloodstream infection, or urinary tract infection).
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 29 September-5 October 2019 and includes updates on Ebola virus disease, extensively drug-resistant Klebsiella pneumoniae, mass gathering monitoring (Japan, Rugby World Cup 2019), Middle East respiratory syndrome coronavirus, Plasmodium cynomolgi infection, poliomyelitis, West Nile virus, and yellow fever.
Carbapenem resistance in Enterobacteriaceae such as Klebsiella pneumoniae and Escherichia coli poses a significant threat to patients and healthcare systems in all European Union/European Economic Area (EU/EEA) countries. Carbapenem-resistant Enterobacteriaceae (CRE) infections are associated with high mortality, primarily due to delays in administration of effective treatment and the limited availability of treatment options.